The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
Abstract
BACKGROUND: Treatment of Alzheimer's disease with acetylcholinesterase inhibitors can result in symptomatic benefits, but patients often show variable responses. The objective of this post hoc analysis was to investigate relationships between easily identifiable baseline characteristics/demographics and cognitive response in patients treated with either donepezil 23 mg/d or 10 mg/d and to identify factors potentially influencing response. METHODS: A post hoc analysis was conducted using data from a large, 24-week, randomized, double-blind, international study enrolling patients with moderate to severe Alzheimer's disease (baseline Mini-Mental State Examination [MMSE], 0-20) (NCT 00478205). Cognitive changes in subgroups of patients based on selected baseline and demographic characteristics were compared using the least squares mean changes in Severe Impairment Battery scores at Week 24. Univariate and multivariate analyses were also performed. RESULTS: Donepezil 23 mg/d provided statistically significant incremental cognitive benefits over donepezil 10 mg/d irrespective of baseline functional severity, measured by scores on the Alzheimer's Disease Cooperative Study-Activities of Daily Living-severe version (P < 0.05). When patients were categorized by baseline cognitive severity (MMSE score), significant benefits of donepezil 23 mg/d over 10 mg/d were seen in both subgroups when based on MMSE scores of 0-9 versus 10-20 (P < 0.02 and P < 0.01, respectively), and in the more severe subgroup when based on MMSE scores of 0-16 versus 17-20 (P < 0.0001 and P > 0.05). Statistically significant incremental cognitive benefits of donepezil 23 mg/d over 10 mg/d were also observed regardless of age, gender, weight, or prestudy donepezil 10 mg/d treatment duration (P < 0.05). In the multivariate analysis, the only significant interaction was between treatment and baseline MMSE score. CONCLUSIONS: The cognitive benefits of donepezil 23 mg/d over 10 mg/d were achieved regardless of the patient's age, gender, weight, duration of prior donepezil 10 mg/d, and functional severity. The influence of baseline cognitive severity on response seemed to be dependent on the level of impairment, with cognitive benefits of donepezil 23 mg/d over 10 mg/d most apparent in those patients at a more advanced stage of disease. These data may be useful in helping practicing physicians make informed decisions for their patients with advanced Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A post hoc analysis suggested that the improvement in cognition caused by 23 mg/d donepezil over 10 mg/d donepezil was not correlated with the age, weight, or sex of AD patients or the duration of treatment with previous low doses of donepezil.429”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [429]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, M., Veloso, F., Moline, M., Yardley, J., Brand-Schieber, E., Bibbiani, F., Zou, H., Hsu, T., & Satlin, A. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-57 · Cited by 95
Self-citationAge and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials
Bernick, C., Cummings, J., Raman, R., Sun, X., & Aisen, P. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3758 · Cited by 85
Self-citation
Research works printed but not linked: 22
- Doody RS, Cummings JL, Farlow MR: Reviewing the role of donepezil in the treatment of Alzheimer’s disease. Curr Alzheimer Res. 2012, 9: 773-781. 10.2174/156720512802455412. · DOI
- Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG: Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004, 19: 624-633. 10.1002/gps.1133. · DOI
- Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T: Donepezil treatment of patients with severe Alzheimer’s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008, 25: 399-407. 10.1159/000122961. · DOI
- Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H: Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan. Psychogeriatrics. 2009, 9: 50-55. 10.1111/j.1479-8301.2009.00291.x. · DOI
- Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A: Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010, 32: 1234-1251. 10.1016/j.clinthera.2010.06.019. · DOI · Paper page
- Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K: Donepezil treatment in severe Alzheimer’s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009, 25: 2577-2587. · DOI
- Evans M, Ellis A, Watson D, Chowdhury T: Sustained cognitive improvement following treatment of Alzheimer’s disease with donepezil. Int J Geriatr Psychiatry. 2000, 15: 50-53. 10.1002/(SICI)1099-1166(200001)15:1<50::AID-GPS75>3.0.CO;2-M. · DOI
- Connelly PJ, Prentice NP, Fowler KG: Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2005, 76: 320-324. 10.1136/jnnp.2004.043539. · DOI
- Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001, 58: 417-422. 10.1001/archneur.58.3.417. · DOI
- Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000, 11: 19-27. 10.1159/000051228. · DOI
- Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J: Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer’s disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012, 33: 164-173. 10.1159/000338236. · DOI
- Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J: Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012, 27: 421-432. 10.1177/1533317512454708. · DOI
- Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E: Age at onset is associated with disease severity in Lewy body variant and Alzheimer’s disease. NeuroReport. 2002, 13: 1825-1828. 10.1097/00001756-200210070-00028. · DOI
- Mungas D, Reed BR, Ellis WG, Jagust WJ: The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 2001, 58: 1243-1247. 10.1001/archneur.58.8.1243. · DOI
- Van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, Van der Flier WM: Most rapid cognitive decline in APOE epsilon4 negative Alzheimer’s disease with early onset. Psychol Med. 2009, 39: 1907-1911. 10.1017/S0033291709005492. · DOI
- Frisoni GB, Manfredi M, Geroldi C, Binetti G, Zanetti O, Bianchetti A, Trabucchi M: The prevalence of apoE-epsilon4 in Alzheimer’s disease is age dependent. J Neurol Neurosurg Psychiatry. 1998, 65: 103-106. 10.1136/jnnp.65.1.103. · DOI
- Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS: Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010, 6: 412-419. 10.1016/j.jalz.2009.12.003. · DOI
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001/jama.291.3.317. · DOI · Paper page
- Sabbagh M, Cummings J: Progressive cholinergic decline in Alzheimer’s Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011, 11: 21-10.1186/1471-2377-11-21. · DOI
- Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000, 48: 391-395. 10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H. · DOI
- Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer’s disease. J Clin Psychopharmacol. 2002, 22: 615-620. 10.1097/00004714-200212000-00012. · DOI
- Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999, 281: 1401-1406. 10.1001/jama.281.15.1401. · DOI · Paper page
Cited by
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Walczak-Nowicka, Ł. J., & Herbet, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179290 · Cited by 335
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Metadata
- Authors
- Sabbagh, M., Cummings, J., Christensen, D., Doody, R., Farlow, M., Liu, L., Mackell, J., & Fain, R.
- Venue
- BMC Geriatrics
- Published
- 2013-06-06
- Volume
- 13
- Issue
- 1
- ISSN
- 1471-2318
- Cited by
- 23
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. https://app.cochat.ai/papers/10.1186/1471-2318-13-56
- The paper
- Sabbagh, M., Cummings, J., Christensen, D., Doody, R., Farlow, M., Liu, L., Mackell, J., & Fain, R. (2013). Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response. BMC Geriatrics. https://doi.org/10.1186/1471-2318-13-56
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.